Loading news...
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Earnings and Valuation This table compares Athira
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares Prime
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares Athira Pharma and
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year
DNB Asset Management AS purchased a new stake in Prime Medicine, Inc. (NYSE: PRME) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 182,133 shares of the company's stock, valued at approximately $1,009,000. DNB Asset Management AS owned 0.14% of Prime
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago.
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment -- -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 -- CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2025 and provided a business update.
MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Chief Executive Officer of the Company. Mr. Turpin succeeds Alexandre Côté, who will step down from his position on February 28, 2026, while remaining on the Board of Directors and retaining responsibility for special projects.
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences:
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Profitability This table compares Prime Medicine and
Shares of Prime Medicine, Inc. (NYSE: PRME - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12
MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has secured exclusive licenses from Prime Capital Investments Inc. for the rights to certain Beach Day Every Day ("BDED") trademarks, in exchange for royalties and marketing and promotion fees. These licenses will allow Prime to use the BDED brand exclusively in connection with the production and commercialization of ready-to-drink beverages and low-calorie cola beverages in North America (excluding Québec). The licenses have a five-year term.
Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Profitability This table compares Eloxx Pharmaceuticals and Prime
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D.
MONTREAL, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a first closing of its previously announced non-brokered private placement offering of units of the Company (the “Unit Offering”) for gross proceeds of $450,000. As a result, the Company issued 7,500,015 common shares in the capital of the Company (the “Common Shares”) and 7,500,015 warrants. Each warrant entitles the holder to purchase one Common Share at a price of $0.06 per share for a period of three (3) years from the issuance date. No finders' fee was paid.
Prime Medicine is maintained at a "Buy" rating due to advancing in vivo Prime Editing programs for Wilson's Disease [PM577] and AATD [PM647]. PM577 targets Wilson's Disease with a strategic focus on anchor mutation H1069Q, enabling future expansion to additional ATP7B mutations. Key catalysts include IND/CTA filings for PM577 and PM647 in 2H 2026, with initial clinical data readouts expected in 2027.
Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price